Navigation Links
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
Date:3/4/2009

utic; the Company's expectations as to the success of its research and development programs in 2009 and beyond, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs and the Company's planned expansion of such programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... IL (PRWEB) March 25, 2015 ... Symmetry® Top-Loading Balances and Analytical Balances to get ... expanded line of weighing balances from the trusted ... Toploading Balances increase your efficiency by providing ... variety of samples. Weighing modes include parts counting, ...
(Date:3/25/2015)... CORAL SPRINGS, Fla. , March 25, 2015 ... (HIT) strategy and management consulting firm, has launched ... reference publication to simplify tracking of ePrescribing regulatory ... "The ePrescribing regulatory landscape continues to ... offerings to deliver what the industry, and ultimately ...
(Date:3/25/2015)... HAGUE, Netherlands , March 25, 2015  EndoStim ... for chronic gastro-esophageal reflux disease (GERD) in the March ... Surgery . 2015; 157(3):556-567 ], establishing the long term ... The study included 25 patients with severe GERD ... prescribed daily proton pump inhibitor (PPI) medication for an ...
(Date:3/25/2015)... NEW YORK , March 25, 2015 ... has released today version 4 of Face2Gene, ... Novel Analysis from computers, as well as mobile devices. ... patterns of human malformations to present comprehensive and up-to-date ... the Annual Clinical Genetics Meeting, ACMG 2015, in ...
Breaking Biology Technology:New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Point-of-Care Partners Launches the ePrescribing State Law Capsule 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3FDNA Releases a Multi-Platform Version of Face2Gene, a Genetic Search and Reference Solution at ACMG 2015 2
... Ltd (ASX: PXS; Nasdaq: PXSL) announced today that ... fibrosis demonstrated excellent lung,function improvement following three months ... current marketed product rhDNase(1). The,improvement in lung function ... a previous study following two weeks of treatment., ...
... Therapeutics Corporation,today announced the appointment of Bruce A. ... member of its Board of Directors. Mr. Peacock ... LLC. Previously, he served,as the CEO or was ... several,successful entrepreneurial healthcare companies operating in therapeutic,diagnostic and ...
... 2008 In this report,entitled "MedPredict Thought ... experts discuss the key controversies,surrounding development of ... the,biopharmaceutical industry is underestimating the size of ... panel, there are a number of factors,stymieing ...
Cached Biology Technology:Cystic Fibrosis Trial In Children Returns Positive Data 2Cystic Fibrosis Trial In Children Returns Positive Data 3Cystic Fibrosis Trial In Children Returns Positive Data 4Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer 2New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated 2
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
(Date:3/12/2015)... Va. , March 12, 2015 IriTech, ... and a member of the Texas Instruments Design Network, ... Naidu has demonstrated its IriShield USB MK2120U device ... scanning facility for pension distribution. The ... assembled to be marketed in India ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... Institute of Food Research, which is strategically funded ... proteins that destroy bacterial cells to combat potentially ... specifically target certain bacteria, and IFR has been ... a common and dangerous source of hospital-acquired infections. ...
... to the puzzle of scaling how patterns stay in ... develops. In a new study appearing in Current Biology, Institute ... Danny Ben-Zvi of the Molecular Genetics Department have shown how ... the vein structure stays perfectly proportioned and their findings ...
... Male adult helminthomorph millipedes usually have one or ... into sexual appendages. These specialized gonopods are used as ... transfer sperm. New research published in BioMed Central,s open ... in detail at millipede development and the internal reorganization ...
Cached Biology News:Tuning natural antimicrobials to improve their effectiveness at battling superbugs 2Scale models 2The secret life of millipedes 2
... mixture excluding l-[U-14C]methionine, 1.85 MBq, 50 ... sterilized. > 1.85 GBq/mg atom ... Mixture of Ala, Arg, Asp, ... Phe, Pro, Ser, Thr, Tyr and ...
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
...
...
Biology Products: